Jeff Nagge

Dr. Nagge’s clinical and research interests have evolved over the years to encompass both the innovative use of artificial intelligence (AI) in pharmacy education and the optimization of anticoagulation and antihypertensive therapy. His work in AI has garnered multiple prestigious awards, positioning him as a leading expert in integrating advanced technologies into clinical training.

In addition to his focus on AI, Dr. Nagge’s practice-based research includes optimizing both anticoagulation and antihypertensive therapy. His research team has recently demonstrated the high quality of community pharmacist-led warfarin management using point-of-care INR testing and decision-support software, documenting the highest reported time in therapeutic range (TTR) in Canadian general practice. They have also studied the prevalence of pseudo-resistant hypertension in primary care and highlighted the underutilization of diuretic therapy in patients with confirmed resistant hypertension.

• Application of artificial intelligence in pharmacy education
• Pharmacy practice-based research in cardiovascular therapeutics
• Clinical pharmacy and pharmacy practice

• 2004 PharmD, University of Toronto, Canada
• 2000 BScPhm, University of Toronto, Canada
• 1995 BSc (Honours Science, Minor in Chemistry), University of Waterloo, Canada

• 2024 Award for Innovation in Education, granted by the Association of Faculties of Pharmacy of Canada, Quebec City, QC
• 2023 Silver Medal, Best Use of Generative AI (Management of Oral Anticoagulation Therapy course), QS Reimagine Education Awards, Abu Dhabi, UAE
• 2022 Excellence in Teaching, Michael G. DeGroote School of Medicine, McMaster University, Waterloo Regional Campus, Kitchener-Waterloo and area Family Medicine Residency program
• 2019 Winner, non-credit programming under 48 hours: Management of Oral Anticoagulation Therapy (MOAT)-online, Canadian Association for University Continuing Education, Hamilton, ON
• 2012, 2014 Interprofessional Preceptor of the Year Award, Michael G. DeGroote School of Medicine, McMaster University, Kitchener-Waterloo and area Family Medicine Residency program
• 2011 Excellence in Teaching – Academic (undergraduate), Michael G. DeGroote School of Medicine, McMaster University, Waterloo Regional Campus

• Dr. Nagge was appointed as the founding Director of the University of Waterloo School of Pharmacy’s Ambulatory Care Pharmacy Residency Program in 2016.
• He continues to practice as a clinical consultant at the Centre for Family Medicine Academic Family Health Team in Kitchener, where he has managed a referral-based hypertension clinic since 2007. His earlier contributions include the development of several innovative clinical services such as a point-of-care anticoagulation clinic and arterial and venous thrombosis clinics, all of which were groundbreaking at the time of their inception.

• Champigny J, Nagge J. Identifying pseudo-resistant hypertension and optimizing thiazide diuretics for confirmed resistant cases in primary care. Canadian Pharmacists Journal. Accepted for publication, April 2024.
• Morrison L, Nagge J. The quality of community warfarin management across two provinces in Canada: A cross-sectional observational study. Canadian Pharmacists Journal 2024;157(2):77-83.
• Pelletier R, Nagge J, Gamble JM. Variation in annual risk of major bleeding estimates among web and mobile calculators for patients with atrial fibrillation. Canadian Family Physician 2022;68(4):e127-e135.
• Waked K, Nagge J, Grindrod K. Managing hypertension in primary care. Canadian Family Physician 2019;65(10):725-9.
• Grindrod KA, Nagge J. Simplifying QT prolongation for busy clinicians. Canadian Family Physician 2019;65(4):268-70.
• Nagge J, Killeen R, Jennings B. Using a course pilot in the development of an online problem-based learning (PBL) therapeutics course in a post-professional PharmD program. Currents in Pharmacy Teaching and Learning 2018;10(2):231-4.
• Nagge J, Lee-Poy MF, Richard CL. Evaluation of a unique interprofessional education program involving medical and pharmacy students. American Journal of Pharmaceutical Education 2017;81(10): Article 6140.
• Dhalla IA, Gomes T, Yao Z, Nagge J, Persaud N, Hellings C, Mamdani MM, Juurlink DN. Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: A population-based cohort study. Annals of Internal Medicine 2013;158(6):447-455.
• Nagge J, Juurlink DN. A population-based comparison of the cardiovascular protective effects of hydrochlorothiazide and chlorthalidone. Circulation. 2007;116:459.
• Nagge J, Knowles S, Shear N, Juurlink D. Pseudoephedrine-induced toxic epidermal necrolysis. Archives of Dermatology 2005;141:907-8.
• Nagge J, Crowther M, Hirsh J. Is renal impairment a contraindication to the use of low molecular weight heparin? Archives of Internal Medicine 2002;162:2605-9.